Menarini is the largest Italian multinational biopharmaceutical company with over 16,000 employees worldwide and presence in more than 100 countries, including Europe, Africa, Middle East, Asia-Pacific, Central and Latin America.
Founded in 1886, Menarini markets products in key therapeutic fields including respiratory, cardiovascular, gastroenterology, metabolism, antibiotics, diabetes, anti-inflammatories and analgesics.
Fungal nail infection (Onychomycosis) is considered as the most common nail problem. Nails become discolored, thickened and cracked making them fragile and lusterless. Topical products are clinically proven to treat nail fungus. The no filing and easy to use nail care brands of A. Menarini aid in the treatment of fungal nail infection by improving the appearance of discolored, thickened, and cracked nails and by increasing hydration to keep nails in good condition. A. Menarini's Nail Care portfolio is a market leader in Asia Pacific with brands already available in 7 countries and 3 more countries in Q1 2016.
Menarini: Top Ten Most "Patient Friendly" Companies
An independent Corporate Reputation Survey of Pharma Companies, including 800 patient groups in 43 countries worldwide, ranked Menarini amongst the world's top ten Pharmaceutical companies closest to patients' needs.
Please refer to the News Corner for the full information about the survey.
Menarini Asia-Pacific is part of the world's largest Italian biopharmaceutical company – Menarini Group which was founded 1886 and has over 16,000 employees in more than 100 countries. Menarini Asia-Pacific's vision is to be a leading provider of important healthcare brands to improve the lives of people in the region. Menarini Asia-Pacific operates across the entire commercial value chain, from clinical development, regulatory approval and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields, including Consumer Health, Dermatology, Primary Care, Allergy/Respiratory, Cardiovascular, Oncology/Specialty Care and Men's Health.
As Menarini Asia-Pacific expands rapidly, demonstrating ethical leadership is a key priority. We strive to have employees who are proud to work for us and whom customers and partners want to do business with.
Smile for Good 50 is a fundraising campaign initiated by employees in regional office to support our regional preferred charity Smile Asia.
Menarini Taiwan supports Noordhoff Craniofacial Foundation via charity sales.
Menarini China help Operation Smile by participating in medical missions and supporting surgeon's trainings.
A campaign aim to raise funds for Smile Asia by purchasing cakes that were specially baked for this worthy cause.
Collaborated with Phoenix Clubhouse to help members of the Clubhouse through Care Program.
- MORE NEWS
- Italian CSI (Crime Scene Investigation) Has New Technology for Fighting Crime
Menarini Silicon Biosystem's DEPArray tehnology has been applied in studies with 100% success rate to identify biological samples (blood, saliva and semen) with the corresponding genetic profiles. Thanks to the collaboration between the Italian Police's CSI department and Menarini, this new scientific application is destined to change the world of forensic science. This development has also been published in the journal "Forensic Science International." For more information, please refer to the Press Release.
- COPD: Increasing an Open Dialogue Between Patients and Physicians
Perhaps due to the difficulty of admitting their illness, or perhaps because of a mere difference in terminology and language, 9 out of 10 patients with chronic obstructive pulmonary disease (COPD) do not inform their doctor of their real condition. A study1 published in the International Journal of COPD sheds light on the lack of effective, bi-directional communication which often affects the state of health of patients. The study will be present at the 2017 European Respiratory Society (ERS) Congress, to be held from 9 to 13 September in Milan. For more information, please refer to the Press Release.
- Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24
Selvita S.A. (WSE:SLV), and Berlin-Chemie Menarini, a company of the Menarini Group, announced today that both companies have entered into a global license agreement for SEL24, a dual PIM/FLT3 inhibitor currently in Phase I/II trials in acute myeloid leukemia (AML) patients. For more information, please refer to the Press Release.
- Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries
Melinta Therapeutics, a privately held company developing novel antibiotics to great serious bacterial infections, and Menarini Group announced the signing of a development and commercialization agreement. As part of this agreement, Melinta has granted the Menarini Group exclusive rights to commercialize Delafloxacin an investigational anionic fluoroquinolone, under their own brands in 68 countries in Europe, Asia-Pacific including China, South Korea, and Australia (Japan excluded), and the Commonwealth of Independent States (CIS) including Russia. For more information, please refer to the Press Release.
Among other philanthropic activities, the International Menarini Foundation organizes international congresses free of charge - over 370 conferences worldwide to date, addressing innovative scientific issues and topics of specific interest, hosting Nobel Prize laureates and always being committed to spread the highest science education around the world. Other top-notch scientific educational activities include Training Workshops, CME/EBAC/EACCME Accredited Training Courses, e-library Multimedia Material and Distance-Learning Events.